RxDoctor Payments Data

Mukeshbhai Patel, MD

Cardiovascular Disease · Hobbs, NMNPI 1639276934

Payments from drug & device makers

$245in general payments, 2019–2025

Across 11 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$184
  • E.r. Squibb & Sons, L.L.C.$18
  • Tactile Systems Technology Inc$16
  • Johnson & Johnson$16
  • Novo Nordisk$11

What the payments were for

  • Food & beverage$22291%
  • Education$239%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$245 in reported general payments places this provider in the 15th percentile of 101 cardiovascular disease providers in New Mexico.

See all cardiovascular disease providers in New Mexico

Medicare billing

Part B allowed, 2024
$234,965
Medicare patients
521
Services billed
1,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban154$153,609
TrulicityDulaglutide15$38,365
XareltoRivaroxaban36$37,172
JanuviaSitagliptin Phosphate21$29,722
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$26,387
BrilintaTicagrelor19$17,022
FarxigaDapagliflozin Propanediol12$15,687
OzempicSemaglutide13$13,880
Potassium Chloride201$8,161
Metoprolol Succinate276$6,630
SymbicortBudesonide/Formoterol Fumarate21$6,168
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$4,982
Levothyroxine Sodium301$4,971
Amlodipine Besylate412$4,493
Atorvastatin Calcium285$3,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Brilinta, Farxiga, Symbicort$184$65,26371 claims
Johnson & JohnsonXarelto$16$37,17236 claims
Novo NordiskOzempic$11$13,88013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 101 cardiovascular disease providers in New Mexico.

Other cardiovascular disease in Hobbs

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →